Grigoriy Rekhtman

1.2k total citations · 1 hit paper
5 papers, 744 citations indexed

About

Grigoriy Rekhtman is a scholar working on Pathology and Forensic Medicine, Infectious Diseases and Genetics. According to data from OpenAlex, Grigoriy Rekhtman has authored 5 papers receiving a total of 744 indexed citations (citations by other indexed papers that have themselves been cited), including 3 papers in Pathology and Forensic Medicine, 2 papers in Infectious Diseases and 2 papers in Genetics. Recurrent topics in Grigoriy Rekhtman's work include Lymphoma Diagnosis and Treatment (3 papers), HIV/AIDS drug development and treatment (2 papers) and Chronic Lymphocytic Leukemia Research (2 papers). Grigoriy Rekhtman is often cited by papers focused on Lymphoma Diagnosis and Treatment (3 papers), HIV/AIDS drug development and treatment (2 papers) and Chronic Lymphocytic Leukemia Research (2 papers). Grigoriy Rekhtman collaborates with scholars based in Ukraine, United States and Russia. Grigoriy Rekhtman's co-authors include Tadeusz Robak, Helgi van de Velde, Jean‐Luc Harousseau, Martin Kropff, Halyna Pylypenko, Bertrand Arnulf, Philippe Moreau, Maria Grishunina, Dixie‐Lee Esseltine and Zvenyslava Masliak and has published in prestigious journals such as Blood, The Lancet Oncology and Haematologica.

In The Last Decade

Grigoriy Rekhtman

5 papers receiving 716 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study

2011 661 citations Philippe Moreau, Halyna Pylypenko et al. The Lancet Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Grigoriy Rekhtman Ukraine	4	538	445	371	165	114	5	744
Maria Grishunina Russia	2	524 1.0×	441 1.0×	352 0.9×	105 0.6×	62 0.5×	3	666
Jessica Anderson United States	3	682 1.3×	765 1.7×	406 1.1×	137 0.8×	103 0.9×	5	1.0k
A. V. Shubina Russia	3	526 1.0×	442 1.0×	352 0.9×	106 0.6×	62 0.5×	4	669
Daniela Hoehn United States	15	257 0.5×	276 0.6×	199 0.5×	188 1.1×	219 1.9×	50	674
Christine I. Chen Canada	11	527 1.0×	425 1.0×	291 0.8×	290 1.8×	207 1.8×	55	769
David H. Vesole United States	9	164 0.3×	178 0.4×	195 0.5×	144 0.9×	196 1.7×	30	444
Claudius Rudin United Kingdom	7	500 0.9×	352 0.8×	532 1.4×	73 0.4×	73 0.6×	16	845
Abdulkadyrov Km Russia	11	776 1.4×	391 0.9×	417 1.1×	282 1.7×	88 0.8×	87	996
Patrizia Falco Italy	16	1.2k 2.3×	1.0k 2.3×	763 2.1×	153 0.9×	62 0.5×	41	1.4k
Nishant Tageja United States	15	212 0.4×	188 0.4×	163 0.4×	115 0.7×	76 0.7×	33	516

Countries citing papers authored by Grigoriy Rekhtman

Since Specialization

Citations

This map shows the geographic impact of Grigoriy Rekhtman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Grigoriy Rekhtman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Grigoriy Rekhtman more than expected).

Fields of papers citing papers by Grigoriy Rekhtman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Grigoriy Rekhtman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Grigoriy Rekhtman. The network helps show where Grigoriy Rekhtman may publish in the future.

Co-authorship network of co-authors of Grigoriy Rekhtman

This figure shows the co-authorship network connecting the top 25 collaborators of Grigoriy Rekhtman. A scholar is included among the top collaborators of Grigoriy Rekhtman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Grigoriy Rekhtman. Grigoriy Rekhtman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

5 of 5 papers shown

1.

Poddubnaya, I V, С. М. Алексеев, Kamil Kaplanov, et al.. (2019). Proposed rituximab biosimilar BCD‐020 versus reference rituximab for treatment of patients with indolent non‐Hodgkin lymphomas: An international multicenter randomized trial. Hematological Oncology. 38(1). 67–73. 11 indexed citations

2.

Robak, Tadeusz, Sebastian Grosicki, Krzysztof Warzocha, et al.. (2015). Ofatumumab (O) in combination with fludarabine (F) and cyclophosphamide (C) (OFC) vs. FC in patients with relapsed chronic lymphocytic leukaemia (CLL): results of the phase III study complement 2. Haematologica. 100. 3 indexed citations

3.

Elter, Thomas, Liana Gercheva, Tadeusz Robak, et al.. (2011). Fludarabine plus alemtuzumab versus fludarabine alone in patients with previously treated chronic lymphocytic leukaemia: a randomised phase 3 trial. The Lancet Oncology. 12(13). 1204–1213. 64 indexed citations

4.

Moreau, Philippe, Halyna Pylypenko, Sebastian Grosicki, et al.. (2011). Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. The Lancet Oncology. 12(5). 431–440. 661 indexed citations breakdown →

5.

Moreau, Philippe, Halyna Pylypenko, Sebastian Grosicki, et al.. (2010). A Phase 3 Prospective Randomized International Study (MMY-3021) Comparing Subcutaneous and Intravenous Administration of Bortezomib In Patients with Relapsed Multiple Myeloma. Blood. 116(21). 312–312. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact